BioTime CEO Dr. Michael West to Present Keynote Address at China-USA Scientific Forum of Stem Cell and Regenerative Medicine

BioTime, Inc. (OTCBB:BTIM) Chief Executive Officer Michael West, Ph.D. will deliver the keynote presentation on Tuesday, September 22, 2009 at the China-USA Scientific Forum of Stem Cell and Regenerative Medicine in Beijing, China. Dr. West's presentation is titled “The New Era of Regenerative Medicine—Induced Pluripotent Stem Cells and Beyond.”

Dr. Walter Funk, BioTime’s Vice President–Stem Cell Research, will speak in place of Dr. West at the 2009 World Stem Cell Summit meeting in Baltimore, Maryland on Wednesday, September 23, 2009. Dr. Funk's presentation is titled “Regenerative Medicine 2.0—Solving the Challenge of Purity and Identity in Stem Cell Therapies.” The presentation will address the challenges the regenerative medicine (ReGEN) industry is currently facing due to cellular contamination producing undesired cell and tissues at the site of engraftment and the potential use of BioTime’s purification technology to mitigate this problem.

Dr. Funk's presentation will also include a discussion of PureStem™ cell lines that exhibit markers for becoming embryonic progenitors of cartilage cells. Dr. West's presentation will be available on September 22, 2009, and Dr. Funk’s presentation will be available online on September 23, 2009 at http://www.biotimeinc.com.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. BioTime develops and markets research products in the field of stem cells and regenerative medicine through its wholly owned subsidiary Embryome Sciences, Inc. In addition to its stem cell products, BioTime markets blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment, and other applications. BioTime's lead product, Hextend®, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive licensing agreements. Additional information about BioTime can be found on the web at www.biotimeinc.com.

Hextend®, PentaLyte®, HetaCool®, Embryomics™, ESpy™, ESpan™, ReCyte™, and PureStem™ are trademarks of BioTime, Inc. ACTCellerate™ is a trademark licensed to Embryome Sciences, Inc. by Advanced Cell Technology, Inc.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://www.b2i.us/irpass.asp?BzID=1152&to=ea&s=0